Hypoxia-activated ROS burst liposomes boosted by local mild hyperthermia for photo/chemodynamic therapy

J Control Release. 2020 Dec 10:328:100-111. doi: 10.1016/j.jconrel.2020.08.035. Epub 2020 Aug 26.

Abstract

Single reactive oxygen species (ROS)-mediated therapy, photodynamic therapy (PDT) or chemodynamic therapy (CDT) is severely hindered in hypoxic solid tumor. Herein, to address the urgent challenge, a hypoxia-activated ROS burst liposome has been fabricated to achieve synergistic PDT/CDT that is initiated by the structural dissociation of poly(metronidazole) liposome in hypoxic tumor microenvironment (TME). The therapeutic enhancement of our ROS-blasting treatment is simultaneously regulated by external light-initiated PDT and endogenous iron oxide nanoclusters-triggered CDT, which is synergistically boosted and amplified by localized mild hyperthermia under 808/660 nm coirradiation. More importantly, in vitro and in vivo experiments demonstrate that electron-affinic poly(aminoimidazole) product from hypoxia-responsive transition of poly(metronidazole) polymers could efficiently enhance hypoxic cell apoptosis and induce solid tumor ablation. Thus, this work offers a potential hypoxia-activated ROS burst-PDT/CDT strategy with a superior antitumor efficacy, highlighting a promising clinical application.

Keywords: Chemodynamic therapy; Hypoxia-responsive; Iron oxide clusters; Photodynamic therapy; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Humans
  • Hyperthermia
  • Hypoxia
  • Liposomes*
  • Photochemotherapy*
  • Reactive Oxygen Species

Substances

  • Liposomes
  • Reactive Oxygen Species